Citations

Clear

2438 citation(s) found for "Ly, Amy".

Serial changes in left and right ventricular global longitudinal strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial
Desai, Milind Y. , Wolski, Kathy , Owens, Amanda, Geske, Jeffrey B. , Saberi, Sima, Cremer, Paul , Tower‐Rader, Albree, Lakdawala, Neal K. , Fermin, Damian , Naidu, Suveeksha, Lampl, Kathy, Sehnert, Amy J. , Fermin, David , Geske, Jeffrey B , Cremer, Paul C , Fermin, David , Okushi, Yuichiro , Popovic, Zoran B , Owens, A, Wang, Andrew

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.2013 Get It

Abstract Background In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), the VALOR-HCM phase 3 randomized, double-blind, placebo-controlled clinical trial demonstrated that mavacamten, reduces the need for septal reduction therapy with sustained improvement in left ventricular outflow tract gradients and symptoms. As a cardiac myosin inhibitor, mavacamten’s mechanism of action reduces myocardial hypercontractility. Global longitudinal strain (GLS), a measure of regional myocardial function, is a more sensitive marker of systolic function and can complement left ventricular ejection fraction (LVEF). Objective We sought to assess serial changes in LV and right ventricular (RV)-GLS in patients enrolled in the VALOR-HCM study. Methods VALOR-HCM included 112 symptomatic obstructive HCM patients (mean 60 years, 51% male, LVEF 68%). Patients assigned to mavacamten at baseline continued the drug for 56 weeks (n=56) and those assigned to placebo crossed over to mavacamten (n=52) from week 16-56 (40-week exposure). LV and RV-GLS assessment was performed according to the current American and European guideline recommendations using a vendor-neutral post processing software. Non-foreshortened apical (4, 3 and 2-chamber) views were used to obtain peak value of LV-GLS. For RV-GLS, RV focused 4-chamber view was used to calculate RV 4-chamber and free wall strain. A more negative strain value is favorable. Results Serial changes in LVEF, average LV-GLS, and RV-GLS (4-chamber and free wall) from baseline to week 56 are shown in the Figure. Despite preserved LVEF at baseline, average baseline LV-GLS was abnormal. There were significant and continued improvements in LV-GLS in the total group from baseline to week 56. 12 patients had transient reduction in LVEF (<50%) requiring temporary drug interruption (permanent discontinuation in 3). The LV-GLS in this subgroup was worse at baseline compared to the total study population, with no significant worsening from baseline through week 56. In the overall population, excluding these 12 patients, LV-GLS demonstrated an improvement sustained through week 56. Both free wall and 4-chamber RV-GLS were abnormal at baseline and remained unchanged from baseline to week 56. Conclusions In the VALOR-HCM trial, despite hypercontractile LVEF at baseline, average baseline LV-GLS was worse than normal reference values. Treatment with mavacamten resulted in an improvement in LV-GLS from baseline through Week 56 (with no significant worsening of LV-GLS in the subgroup who experienced any reduction in LVEF <50%), suggesting a favorable long-term impact on regional LV systolic function due to the reduction of cardiac hypercontractility. Additionally, there was no significant detrimental impact on RV systolic function on serial GLS assessment.Serial changes in LV and RV GLS in VALOR
Serial changes in left atrial strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial
Desai, Milind Y. , Wolski, Kathy , Owens, Amanda, Geske, Jeffrey B. , Saberi, Sima, Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Fermin, Damian , Naidu, Suveeksha, Lampl, Kathy, Sehnert, Amy J. , Fermin, David , Geske, Jeffrey B , Cremer, Paul C , Fermin, David , Okushi, Yuichiro , Popovic, Zoran B , Owens, A, Wang, Andrew , Fermin, D

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.013 Get It

Abstract Background In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), the VALOR-HCM phase 3 randomized, double-blind, placebo-controlled clinical trial demonstrated that mavacamten, a cardiac myosin inhibitor, reduces the eligibility for septal reduction therapy with sustained improvement in left ventricular (LV) outflow tract gradients and symptoms. Mavacamten also resulted in favorable cardiac remodeling, including improvement in left atrial volume index (LAVI), LV diastolic function, and biomarkers (NT-proBNP and troponin T). However, the impact of mavacamten on LA function is not known. Objective We sought to assess serial changes in LA strain measures in patients enrolled in the VALOR-HCM trial. Methods VALOR-HCM included 112 symptomatic obstructive HCM patients (mean age 60 years, 51% male). Patients assigned to mavacamten at baseline (n=56) continued therapy for 56 weeks and those assigned to placebo crossed over to mavacamten (n=52) from week 16-56 (40-week exposure). Echocardiographic LA strain assessment was performed according to the current American and European guideline recommendations, using a vendor-neutral post processing software. For assessment of LA strain components (reservoir, conduit, and contraction), the non-foreshortened apical 4-chamber view was utilized. The zero reference was set at end-diastole. Results Serial changes in LAVI and all components of mean LA strain from baseline to week 56 are shown in the Figure. At baseline, LAVI and all mean LA strain values were worse than reported normal mean thresholds. There was a continued and significant improvement in all 3 LA strain values, from baseline to week 56, along with a significant reduction in LAVI. Improvement in LAVI was seen earlier than improvements in LA strain. There was a significant inverse correlation between change in mean LAVI and LA reservoir strain from baseline to week 56 (r= -0.42, p<0.001). Conclusions In the VALOR-HCM trial, average LAVI and baseline LA strain values were significantly worse than reported normal thresholds. Treatment with mavacamten resulted in an improvement in LAVI and LA strain values from baseline through week 56 suggesting a sustained favorable impact on cardiac remodeling. The advantageous cardiac remodeling associated with long-term treatment with mavacamten may in turn have a favorable impact on the observed high burden of atrial tachyarrhythmias in HCM.Serial changes in LA strain in VALOR-HCM
S1248 Characteristics and Real-World Outcomes of Patients Treated With Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection (rCDI)
Khanna, Sahil , Goldenberg, David M. , Seo, Sanghyuk, García-Horton, Viviana , Gao, Yipeng , Kim, Hannah , Ormenaj, Loren, Guo, Amy , Seo, Sanghyuk, Yang, Min

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S887-S888

10.14309/01.ajg.0001034360.16398.08 Get It

Nursing Home Palliative Care Referral Process, Barriers, and Proposed Solutions: A Qualitative Study
Cole, Connie S. , Jackson, Amy , Bennett, Claire , Fink, Regina M. , Unroe, Kathleen T. , Bennett, C Robert, Bennett, C Robert , Levy, Cari R. , Carpenter, Joan G.

Mayo Clinic

Journal of Applied Gerontology | October 21, 2024 | Volume: 44 | Issue: 4 | Pages: 582-590

10.1177/07334648241286326 | PMID 39431974 Get It

Despite evidence that specialized care for seriously ill nursing home (NH) residents is needed, barriers to accessing palliative care (PC) remain. A significant issue is the complexity of the referral process that inhibits timely and equitable access to care. This qualitative descriptive study explored the PC referral process in NHs. Using rapid qualitative analysis with semi-structured interview data from NH staff, primary care, and specialty PC providers ( N = 17) in six states, this study outlines a multistep referral process along with barriers and proposed solutions. Key recommendations include comprehensive PC education program development, implementation of an evidence-based PC screening tool, and the holistic integration of PC services in NHs.
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Aldoss, Ibrahim , Kopmar, Noam E. , Lin, Chenyu , Dekker, Simone E. , Gupta, Vishal, O’Connor, Timothy E. , Jeyakumar, Nikeshan , Muhsen, Ibrahim N. , Valtis, Yannis K. , Zhang, Amy , Miller, Kate , Ahmed, Mohamed , Schwartz, Marc S. , Tracy, Sean , Mukherjee, Akash , Ladha, Abdullah , Guzowski, Caitlin, Hoeg, Rasmus T. , Moore, Jozal , Connor, Matthew P. , Hill, LaQuisa C. , Tsai, Stephanie B., Sasine, Joshua , Solh, Melhem , Koura, Divya, Veeraputhiran, Muthu, Park, Jae H. , Bachanová, Veronika , Galal, Ahmed , Pullarkat, Vinod , Muffly, Lori , Oliai, Caspian , Yaghmour, George , Sutherland, Katherine, Zambrano, Héctor, Bradshaw, Danielle , Kubiak, Michal , Mountjoy, Luke , Malik, Shahbaz A. , Shaughnessy, Paul , Stefan, Maryann, O'Dwyer, Kristen M., Blunk, Betsy, Bishop, Michael R. , Aldoss, Ibrahim , Kopmar, Noam E , Lin, Chenyu , Gupta, Vishal K , Muhsen, Ibrahim N , Valtis, Yannis , Miller, Katharine , Chen, Evan , Mercadal, Santiago , Tracy, Sean I , Dholaria, Bhagirathbhai R , Battiwalla, Minoo , Logan, Aaron C , Ladha, Abdullah , Hilal, Talal , Connor, Matthew , Hill, LaQuisa C , Sasine, Joshua , Solh, Melham M , Kota, Vamsi , Frey, Noelle V , Park, Jae H , Luskin, Marlise R , Stock, Wendy , Cassaday, Ryan D , Muffly, Lori , Bachanova, Veronika , Roloff, Gregory W. , Ahmed, Naveed, Dykes, Kaitlyn C. , Schwartz, Marc, Dholaria, Bhagirathbhai , Battiwalla, Minoo , Hilal, Talal , Tsai, Stephanie B., Kota, Vamsi , Leonard, Jessica T , Frey, Noelle V. , Stock, Wendy , Cassaday, Ryan D. , Shah, Bijal , Faramand, Rawan , Oliai, Caspian H , Majhail, Navneet S. , Mathews, John Abraham , Advani, Anjali S. , O'Dwyer, Kristin , Lee, Catherine J , Bishop, Michael Russell

Mayo Clinic

Journal of Clinical Oncology | October 17, 2024 | Volume: 43 | Issue: 5 | Pages: 558-566

10.1200/jco.24.00321 | PMID 39418622 Get It

PURPOSE On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes of patients treated with brexu-cel as a standard therapy. METHODS We developed a collaboration across 31 US centers to study adults with B-ALL who received brexu-cel outside the context of a clinical trial. Data were collected retrospectively from October 2021 to October 2023. Toxicities were graded per American Society for Transplantation and Cellular Therapy guidelines for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). RESULTS At the time of data lock, 204 patients had undergone apheresis and 189 were infused. Median follow-up time was 11.4 months. Forty-two percent of patients received brexu-cel in morphologic remission and would have been ineligible for participation in ZUMA-3. After brexu-cel, 151 achieved complete remission (CR), of which 79% were measurable residual disease (MRD) negative remissions. Median progression-free survival (PFS) was 9.5 months and median overall survival was not reached. Grade 3-4 CRS or ICANS occurred in 11% and 31%, respectively. In multivariable analysis, patients receiving consolidative hematopoietic cell transplantation (HCT; hazard ratio, 0.34 [95% CI, 0.14 to 0.85]) after brexu-cel had superior PFS compared with those who did not receive any consolidation or maintenance therapy. CONCLUSION Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved PFS.
Evaluating adoption and reach in a pragmatic randomized trial of community paramedicine for intermediate acuity patient care
Ridgeway, Jennifer L. , Sundt, Wendy J., Krpata, Tami, Glasgow, Amy E. , Smith-Stellflug, Jamie L, Juntunen, Michael B. , Liedl, Chad P., Hentz, Joseph G. , McCoy, Jessica, Sundt, Wendy J S, Krpata, Tami S, Glasgow, Amy, Smith, Olivia A, Lampman, Michelle A. , Menser, Terri L, McCoy, Jessica J, Ridgeway, Jennifer L , Smith, Jamie L , Smith, Olivia A., Menser, Terri , McCoy, Rozalina G.

Mayo Clinic

Journal of Clinical and Translational Science | October 17, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1017/cts.2024.646 | PMID 39655042 Get It

Abstract Introduction: Pragmatic trials aim to speed translation to practice by integrating study procedures in routine care settings. This study evaluated implementation outcomes related to clinician and patient recruitment and participation in a trial of community paramedicine (CP) and presents successes and challenges of maintaining pragmatic study features. Methods: Adults in the pre-hospital setting, emergency department (ED), or hospital being considered for referral to the ED/hospital or continued hospitalization for intermediate-level care were randomized 1:1 to CP care or usual care. Referral and enrollment data were tracked administratively, and patient characteristics were abstracted from the electronic health record (EHR). Enrolled patients completed baseline surveys, and a subset of intervention patients were interviewed. All CPs and a sample of clinicians and administrators were invited to complete a survey and interview. Results: Between January 2022 and February 2023, 240 enrolled patients (42% rural) completed surveys, and 22 completed an interview; 63 staff completed surveys and 20 completed an interview. Ninety-three clinicians in 27 departments made at least one referral. Factors related to referrals included program awareness and understanding the CP practice scope. Most patients were enrolled in the hospital, but characteristics were similar to the primary care population and included older and medically complex patients. Challenges to achieving representativeness included limited EHR infrastructure, constraints related to patient consenting, and clinician concerns about patient randomization disrupting preferred care. Conclusion: Future pragmatic trials in busy clinical settings may benefit from regulatory policies and EHR capabilities that allow for real-world study conduct and representative participation. Trial registration: NCT05232799.
Polygenic risk scores stratify breast cancer risk among women with benign breast disease
Sherman, Mark E. , Winham, Stacey J. , Vierkant, Robert A. , McCauley, Bryan M. , Scott, Christopher G. , Schrup, Sarah E. , Gaudet, Mia M. , Troester, Melissa A. , Pruthi, Sandhya , Bolla, Manjeet K. , Wang, Qin , Dennis, Joe, Chang‐Claude, Jenny , Obi, Nadia, Aronson, Kristan J. , García‐Closas, Montserrat , Yang, Xiaohong R. , Pharoah, Paul D.P., Easton, Douglas F., Vachon, Celine M, Schrup, Sarah, Radisky, Derek C. , Wang, Qin , Dennis, Joe , Michailidou, Kyriaki , Truong, Therese , Obi, Nadia , Aronson, Kristan J , García-Closas, Montserrat , Chanock, Stephen Jacob , Yang, Xiaohong R , Mavaddat, Nasim , Easton, Doug , Vachon, Celine M. , Winham, Stacey J , Vierkant, Robert A , Scott, Christopher , Gaudet, Mia M , Sherman, Mark E , Degnim, Amy C. , Couch, Fergus J. , Michailidou, Kyriaki , Guénel, Pascal , Truong, Thérèse , Murphy, Rachel A. , Ahearn, Thomas U. , Dunning, Alison M. , Easton, Douglas F.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 16, 2024 | Volume: 117 | Issue: 3 | Pages: 456-464

10.1093/jnci/djae255 | PMID 39412492 Get It

Abstract Background Most breast biopsies are diagnosed as benign breast disease, with 1.5- to 4-fold increased breast cancer risk. Apart from pathologic diagnoses of atypical hyperplasia, few factors aid in breast cancer risk assessment of these patients. We assessed whether a 313–single nucleotide variation (formerly single-nucleotide polymorphism) polygenic risk score stratifies risk of benign breast disease patients. Methods We pooled data from 5 Breast Cancer Association Consortium case-control studies (mean age = 59.9 years), including 6706 participants with breast cancer and 8488 participants without breast cancer. Using logistic regression, we estimated breast cancer risk associations by self-reported benign breast disease history and strata of polygenic risk score, with median polygenic risk score category among women without benign breast disease as the referent. We assessed interactions and mediation of benign breast disease and polygenic risk score with breast cancer risk. Results Benign breast disease history was associated with increased breast cancer risk (odds ratio [OR] = 1.48, 95% confidence interval [CI] = 1.37 to 1.60; P < .001). Polygenic risk score increased breast cancer risk, irrespective of benign breast disease history (Pinteraction = .48), with minimal evidence of mediation of either factor by the other. Women with benign breast disease and polygenic risk score in the highest tertile had more than twofold increased odds of breast cancer (OR = 2.73, 95% CI = 2.41 to 3.09), and those with benign breast disease and polygenic risk score in the lowest tertile experienced reduced breast cancer risk (OR = 0.79, 95% CI = 0.70 to 0.91) compared with the referent group. Women with benign breast disease and polygenic risk score in the highest decile had a 3.7-fold increase (95% CI = 3.00 to 4.61) compared with those with median polygenic risk score without benign breast disease. Conclusion Breast cancer risks are elevated among women with benign breast disease and increase progressively with polygenic risk score, suggesting that optimal combinations of these factors may improve risk stratification.
Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica
Vorasoot, Nisa , Abdulrahman, Yahya, Mateen, Farrah J. , Fryer, James P., Redenbaugh, Vyanka , Sagen, Jessica, Jenkins, Sarah M. , Gorsh, Amy P., Chen, John J. , Ζεκερίδου, Αναστασία , Mills, John R. , Pittock, Sean J. , Pittock, S J , Abdulrahman, Yahya J, Mateen, Farrah , Sagen, Jessica A., Zekeridou, Anastasia , McKeon, Andrew , Flanagan, E P , Chen, John J , Vorasoot, Nisa , Musubire, Abdu Kisekka , McKeon, Andrew , Flanagan, Eoin P.

Mayo Clinic

Annals of Clinical and Translational Neurology | October 15, 2024 | Volume: 11 | Issue: 11 | Pages: 2855-2865

10.1002/acn3.52178 | PMID 39406378 Get It

AbstractObjectiveThis study aimed to evaluate the diagnostic accuracy of dried blood spot (DBS) compared with conventional serum Aquaporin‐4‐IgG (AQP4‐IgG) testing.MethodsProspective multicenter diagnostic study was conducted between April 2018 and October 2023 across medical centers in the United States, Uganda, and the Republic of Guinea. Neuromyelitis optica spectrum disorder (NMOSD) patients and controls collected blood on filter paper cards along with concurrent serum samples. These samples underwent analysis using flow cytometric live‐cell‐based assays (CBA) and enzyme‐linked immunosorbent assay (ELISA) to determine AQP4 serostatus. The accuracy of AQP4‐IgG detection between DBS and serum (gold standard) was compared.ResultsAmong 150 participants (47 cases, 103 controls), there was a strong correlation between DBS and serum samples (Spearman's correlation coefficient of 0.82). The AUC was 0.97 (95% CI: 0.92–0.99). AQP4‐IgG detection through DBS showed 87.0% sensitivity (95% CI: 0.74–0.95) and 100% specificity (95% CI: 0.96–1.00) using CBA, and 65.2% sensitivity (95% CI: 0.43–0.84) and 95.2% specificity (95% CI: 0.76–0.99) using ELISA. Serum ELISA demonstrated 69.6% sensitivity (95% CI: 0.47–0.87) and 98.4% specificity (95% CI: 0.91–0.99). The stability of DBS in detecting AQP4‐IgG persisted over 24 months for most cases.InterpretationThe DBS represents a viable alternative for detecting AQP4‐IgG in resource‐limited settings to diagnose NMOSD, offering high sensitivity and specificity comparable to serum testing. Moreover, DBS has low shipping costs, is easy to administer, and is suitable for point‐of‐care testing.
Clinical Characteristics and Outcomes of Patients With COVID-19 Treated in Mayo Clinic’s Advanced Care at Home Program
Gothot, Rachel A., Haney, A.F., Li, Zhuo, Maita, Karla C. , Valles, Brittane T., Li, Zhuo , Haney, Amy A, Maniaci, Michael J. , Paulson, Margaret R. , Dumic, Igor , Haney, Amy A., Burger, Charles D.

Mayo Clinic

Journal of Patient Safety | October 14, 2024 | Volume: 20 | Issue: 8 | Pages: 605-611

10.1097/pts.0000000000001286 | PMID 39565071 Get It

Objectives Mayo Clinic’s hospital-at-home program, Advanced Care at Home (ACH), launched in 2020. While hospital-at-home literature reported safe and effective care for the general patient population and those with COVID, comparative outcomes between these two groups were unknown. The aim of this retrospective analysis was to compare the outcomes of COVID and non-COVID patients enrolled in ACH and evaluate if COVID patients can be safely treated in this setting. Methods Demographics, clinical characteristics, and safety outcomes were retrospectively analyzed to compare COVID and non-COVID patients discharged from ACH between November 2020 and May 2022. Patient characteristics analyzed included severity of illness (SOI) and risk of mortality (ROM), calculated using All Patient Refined Diagnosis Related Groups (APR-DRG). Hospitalization-specific variables included length of stay (LOS), escalation of care, and 30-day readmission rates. Results Of 1051 patients, 173 (16%) had COVID, and 878 (84%) were non-COVID patients. The average age in the COVID cohort was 66.6 (15.3) years, compared with 72.2 (14.0) in the non-COVID cohort. Extreme SOI was higher in the COVID group (43.3% versus 17.4%), as was extreme ROM (46.2% versus 16.2%), but LOS was shorter (5.7 versus 7 days). Escalation of care (7.5% in COVID cohort versus 8.4%) and 30-day readmission outcomes (9.2% for COVID patients versus 12.9%) were not statistically different between the groups. Conclusions Despite higher SOI and ROM, COVID patients had shorter LOS with outcomes that were not statistically different from non-COVID patients. COVID patients can be safely and efficiently cared for in ACH.